Sanctuary Advisors LLC Has $318,000 Position in Penumbra, Inc. (NYSE:PEN)

Sanctuary Advisors LLC reduced its holdings in shares of Penumbra, Inc. (NYSE:PEN) by 29.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,339 shares of the company’s stock after selling 548 shares during the period. Sanctuary Advisors LLC’s holdings in Penumbra were worth $318,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. True Wealth Design LLC acquired a new stake in Penumbra during the 3rd quarter worth about $26,000. UMB Bank n.a. grew its holdings in Penumbra by 57.4% during the 4th quarter. UMB Bank n.a. now owns 192 shares of the company’s stock worth $46,000 after acquiring an additional 70 shares during the period. Mather Group LLC. grew its holdings in Penumbra by 208.0% during the 4th quarter. Mather Group LLC. now owns 308 shares of the company’s stock worth $73,000 after acquiring an additional 208 shares during the period. Advisors Asset Management Inc. grew its holdings in Penumbra by 11.5% during the 3rd quarter. Advisors Asset Management Inc. now owns 416 shares of the company’s stock worth $81,000 after acquiring an additional 43 shares during the period. Finally, GAMMA Investing LLC grew its holdings in Penumbra by 160.8% during the 4th quarter. GAMMA Investing LLC now owns 446 shares of the company’s stock worth $106,000 after acquiring an additional 275 shares during the period. 88.88% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Penumbra news, CEO Adam Elsesser sold 15,000 shares of Penumbra stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $242.96, for a total transaction of $3,644,400.00. Following the transaction, the chief executive officer now owns 837,582 shares of the company’s stock, valued at $203,498,922.72. This trade represents a 1.76 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Harpreet Grewal sold 167 shares of Penumbra stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $241.28, for a total transaction of $40,293.76. Following the transaction, the director now directly owns 8,530 shares in the company, valued at approximately $2,058,118.40. This represents a 1.92 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.00% of the company’s stock.

Penumbra Price Performance

Shares of NYSE PEN opened at $285.92 on Tuesday. Penumbra, Inc. has a fifty-two week low of $148.00 and a fifty-two week high of $310.00. The stock has a market cap of $11.01 billion, a price-to-earnings ratio of 840.94, a PEG ratio of 2.83 and a beta of 0.53. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01. The firm’s 50-day simple moving average is $264.16 and its 200 day simple moving average is $233.24.

Penumbra (NYSE:PEN) last announced its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.09. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The business had revenue of $315.52 million for the quarter, compared to analysts’ expectations of $311.63 million. As a group, research analysts anticipate that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on PEN shares. Morgan Stanley increased their price target on Penumbra from $240.00 to $260.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 19th. Wells Fargo & Company raised their target price on Penumbra from $275.00 to $305.00 and gave the company an “overweight” rating in a research note on Wednesday, February 19th. Royal Bank of Canada raised their target price on Penumbra from $285.00 to $313.00 and gave the company an “outperform” rating in a research note on Wednesday, February 19th. UBS Group raised their target price on Penumbra from $305.00 to $320.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Finally, Canaccord Genuity Group raised their target price on Penumbra from $323.00 to $340.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Four research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $292.64.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.